智通财经APP讯，帝王国际投资(00928)发布截至2025年3月31日止年度业绩，收益4076.5万港元，同比 下降82.6%;公司拥有人应占亏损4745.3万港元，上年同期溢利1581.8万港元;每股基本亏损2.56港仙。 截至2025年3月31日止年度，集团取得毛利约1273万港元(截至2024年3月31日止年度：约3779万港元)。 集团的整体毛利率为31.23%(截至2024年3月31日止年度：16.17%)。截至2025年及2024年3月31日止年 度，集团的整体毛利主要归因于毛利率较低的酒类销售。本年度约100.00%的销售额来自酒类销售(截至 2024年3月31日止年度：51.29%)。 公司已申请于2025年9月22日上午九时正起恢复公司股份于联交所买卖。 ...

Group 1 - The company, Emperor International Investment (00928.HK), announced a delay in the publication and/or distribution of its 2025 annual results and annual report due to the need for additional time to complete necessary audit procedures [1] - The delay is attributed to the auditor not having received certain confirmations required for the audit, such as bank confirmation letters [1] - Trading of the company's shares remains suspended as a result of these delays [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 King International Investment Limited （股份代號：928） 帝 王 國 際 投 資 有 限 公 司 Life Healthcare Group Limited (1)進一步延遲刊發二零二五年全年業績； (2)董事會會議進一步延期 及 (3)繼續暫停買賣 茲提述本公司日期為二零二五年六月三十日、二零二五年七月十八日、二零二五年八月 八日及二零二五年八月二十二日之公佈（「該公佈」），內容有關（其中包括）(i)延遲刊發本 集團截至二零二五年三月三十一日止財政年度之全年業績（「二零二五年全年業績」）；(ii) 董事會會議延期；及(iii)暫停買賣。除另有界定外，本公佈所用詞彙與該公佈所界定者具 有相同涵義。 根據目前情況及最近與核數師的討論，鑑於本集團審核進度的最新情況，需要額外時間 以完成必要的審核程序，包括但不限於(i)核數師於本公佈日期仍未收到審核所需的若干 確認（如 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 帝王國際投資有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00928 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.05 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.05 | HKD | | 500,000,000 | 本月 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 帝 王 國 際 投 資 有 限 公 司 King International Investment Limited Life Healthcare Group Limited 進一步延遲刊發二零二五年全年業績及寄發二零二五年年報 根據目前情況及最近與核數師的討論，鑑於本集團審核進度的最新情況，需要額外時間 以完成必要的審核程序，包括但不限於(i)核數師於本公佈日期仍未收到審核所需的若干 確認（如銀行確認函）；及(ii)需要額外時間進行終止合併。因此，刊發及╱或寄發二零 二五年全年業績及二零二五年年報（視情況而定）將進一步延遲。 — 1 — （股份代號：928） 內幕消息 (1)進一步延遲刊發二零二五年全年業績； (2)董事會會議進一步延期 及 (3)繼續暫停買賣 本公佈乃由帝王國際投資有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董 事會」）根據香港聯合交易所有限公司證券上市規則（「上市 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 — 1 — 帝 王 國 際 投 資 有 限 公 司 King International Investment Limited Life Healthcare Group Limited （股份代號：928） 內幕消息 (1)進一步延遲刊發二零二五年全年業績； (2)董事會會議進一步延期 及 (3)繼續暫停買賣 本公佈乃由帝王國際投資有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董 事會」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香港法例 第571章證券及期貨條例第XIVA部項下之內幕消息條文而作出。 茲提述本公司日期為二零二五年六月三十日及二零二五年七月十八日之公佈（「該公佈」）， 內容有關（其中包括）(i)延遲刊發本集團截至二零二五年三月三十一日止財政年度之全年 業績（「二零二五年全年業績」）；(ii)董事會會議延期；及(iii)暫停買賣。除另有界 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 帝王國際投資有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00928 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.05 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.05 | HKD | | 500,000,000 | 本月 ...

Group 1 - The company announced the establishment of a joint venture in China, with the company holding 34% and partners holding 63% [1] - The joint venture received capital injections of HKD 3,400,000 from the company and HKD 6,300,000 from partners, with no further funding commitments expected [1] - The formation of the joint venture aims to leverage resources and expertise for mutual benefits, enhancing operational efficiency and product marketing in the healthcare sector [1] Group 2 - The board has decided to add a new core business segment focused on Superoxide Dismutase (SOD), which has unique scientific mechanisms and advantages in industrialization [2] - SOD is expected to be applicable in high-end medical aesthetics, functional foods, and specialized medical fields, supported by intellectual property barriers and core patents [2] - The introduction of the SOD business segment is anticipated to open new growth avenues in biomedicine and upgrade existing consumer businesses, creating a technology-driven valuation system [2]

Group 1 - The core viewpoint of the news highlights the significant stock performance of Emperor International Investment, with a recent increase of 63.29% and a cumulative increase of 172.41% over the past month, outperforming the Hang Seng Index by 18.61% [1][2] - Financial data shows that as of September 30, 2024, Emperor International Investment reported total revenue of 33.534 million yuan, a year-on-year decrease of 55.43%, and a net profit attributable to the parent company of -1.4311 million yuan, a decrease of 193.74% [1] - The company's gross profit margin stands at 2.71%, and its debt-to-asset ratio is 21.08% [1] Group 2 - Currently, there are no institutional investment ratings for Emperor International Investment [2] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 4.17 times, with a median of 5.82 times, while Emperor International Investment has a P/E ratio of 11.66 times, ranking 34th in the industry [2] - Other companies in the health sector have significantly lower P/E ratios, such as Great Health International at 0.56 times and Jingyou Pharmaceutical at 0.68 times [2] Group 3 - Emperor International Investment is a Hong Kong-listed company focused on precision oncology and genetic testing, providing molecular diagnostic solutions and academic research services for clinical doctors, hospitals, cancer patients, and researchers in cancer-related fields [3] - The company’s self-developed genetic testing products cover various types of tumors and are involved in all stages of cancer management, including early screening, auxiliary diagnosis, medication guidance, prognosis assessment, and dynamic monitoring [3] - The company operates laboratories in Beijing and Guangzhou, adhering to strict quality management systems and achieving high scores in various assessments [3]

Company Overview - Emperor International Investment Limited is a Hong Kong-listed company focused on precision oncology and genetic testing [2] - The company provides molecular diagnostic solutions and academic research services for clinical doctors, hospitals, cancer patients, high-risk health individuals, and researchers in cancer-related fields [2] - The company has developed genetic testing products covering various types of tumors, including respiratory, digestive, breast, gynecological, urinary, and head and neck tumors, facilitating early screening, auxiliary diagnosis, medication guidance, prognosis assessment, and dynamic monitoring throughout the cancer management process [2] Financial Performance - As of September 30, 2024, Emperor International Investment reported total revenue of 33.534 million yuan, a year-on-year decrease of 55.43% [1] - The company recorded a net profit attributable to the parent of -1.4311 million yuan, a year-on-year decrease of 193.74% [1] - The gross profit margin stood at 2.71%, and the debt-to-asset ratio was 21.08% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.3 times, with a median of 5.39 times [1] - Emperor International Investment has a P/E ratio of 10.33 times, ranking 28th in the industry [1] - Comparatively, other companies in the health sector have significantly lower P/E ratios, such as Great Health International at 0.56 times and King’s Ray Biotechnology at 1.25 times [1]